TAZ regulates cell proliferation and epithelial--mesenchymal transition of human hepatocellular carcinoma
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Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide, yet little is known about the molecular mechanisms at play. The transcriptional coactivator with PDZ binding motif (TAZ) was investigated as a possible target, as this activator is known to play a role in breast, colorectal, and other types of cancer. Xiao and colleagues studied HCC cancer lines *in vivo* in mice models and *in vitro* and discovered that TAZ is not only abundantly expressed in HCC, but that downregulation of TAZ results in a decrease in proliferation of cancer cells. Furthermore, TAZ knockdown models reversed epithelial--mesenchymal transition, an integral step in the metastases of cancer. This groundbreaking work is both exciting and promising for the future and offers a potential target for further investigation.doi: [10.1111/cas.12587](10.1111/cas.12587)
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Biochemical, biological, and structural properties of romidepsin (FK228) and its analogs as novel histone deacetylase/phosphatidylinositol 3-kinase dual inhibitors
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A complex array of intracellular signaling cascades are involved in normal processes of cell proliferation and turnover. When aberrant processes go unchecked and cell cycle arrest mechanisms are impaired, malignant potential arises from otherwise standard cell signaling molecules. Anticancer drugs are often aimed at reducing or eliminating aberrations in cell signaling, but initial successes are often overcome by resistance mechanisms. Saijo and others report their work on a class of kinase pathway inhibitors that not only inhibit the phosphatidylinositol 3-kinase cascade, but also inhibit histone deacetylases, which are involved in the initiation and propagation of cancer cells. The authors carried out an extensive characterization of this class of compounds, including studies of their molecular structures, dose--response relationships, and interactions with their targets. Through their efforts, the researchers provide a wealth of valuable data that may be used for future drug development.doi: [10.1111/cas.12585](10.1111/cas.12585)
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Sunitinib impedes brain tumor progression and reduces tumor-induced neurodegeneration in the microenvironment
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Malignant glioma is a devastating diagnosis for which available therapies provide only modest benefits. There have been few advances in the care of patients with high grade glioma, but the recent development of temozolomide has provided hope for effective chemotherapeutic interventions. In their work, Hatipoglu and colleagues sought to identify an alternative means of targeting gliomas. Acting through antiangiogenic properties, sunitinib was tested for an ability to impair proliferation of a glial cancer cell culture model. The authors identified a synergistic effect between sunitinib and temozolomide, the current standard chemotherapeutic drug for malignant gliomas. Importantly, not only was sunitinib effective against malignant glial tissue, but it did not affect the normal glial vasculature. These findings suggest that sunitinib may be a suitable agent to be tested in future studies of high grade glioma.doi: [10.1111/cas.12580](10.1111/cas.12580)
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